Conference Coverage

Highlights from ESMO 2016: The Continued Rise of Anti-PD-1 Therapy in the Treatment of NSCLC

October 24, 201618 min
Host: Matt Birnholz, MD Guest: Edward S. Kim, MD, FACP Lung cancer is the leading cause of cancer-associated mortality, with almost 225,000 new cases and over 158,000 deaths estimated in 2016 in the United States alone. Non-small cell lung cancer (NSCLC) represents approximately 85% of those cases. Join us as Dr. Birnholz and Dr. Kim review the data presented at the 2016 annual ESMO conference and discuss the continued rise of anti-PD-1 therapy in the treatment of NSCLC.

Chat About Highlights from ESMO 2016: The Continued Rise of Anti-PD-1 Therapy in the Treatment of NSCLC

For You